Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1440)	3/22/2003 6:42:55 PM
From: scaram(o)uche	Read Replies (2) of 3044

>> Rick's theory is the the two mAbs are binding slightly different epitopes and that this might be the reason for what appears to be a difference in efficacy. << I know that there's not a hint of intent behind it, but that's not correct. The antibodies bind to very different epitopes, one expressed on two relevant (?) intregin molecules and the other (MLN02) on one of the two. I am using "integrin molecule" in the sense of combined alpha and beta chains. More later..... I've been promising the kids a game of handball for about an hour, and my daughter is standing here scowling at me, noting that I just switched to a new subject. But, before I split...... I expected MLN02 to be effective, and I looked at the preclinical data closely when I did a slightly informal (covered by retainer, but not of sufficient depth to go beyond that) DD job on LeukoSite, before they went public. And I fully share Erik's opinion about MLNM's course of action, going forward.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next